Psych Drugs Flashcards
Typical antipsychotics
Dopamine-2 receptor antagonists
Atypical antipsychotics
Serotonin-dopamine antagonists
D2 partial agonists
Indications of typicals
Psychotic disorders Mood disorders Dementia Psychosis secondary to medical conditions, medications, and drugs of abuse Personality disorder Obsessive-compulsive disorder Autism Tourette’s disorder
dopamine-mediated effects: nigrostriatal pathway
EPS (Parkinsonism, Akathisia, Dystonic reactions, Tardive dyskinesia, NMS)
dopamine-mediated effects: mesolimbic pathway
dysphoria
dopamine-mediated effects: mesocortical pathway
worsening negative and cognitive symptoms
dopamine-mediated effects: tuberoinfundibular pathway
Hyperprolactinemia, and resultant galactorrhea, amenorrhea, sexual dysfunction
acute EPS
Dystonia – usually within hours
Akathisia – usually within days
Parkinsonism – usually within days to weeks
chronic/late set EPS
Tardive Dyskinesia usually after 3 months
treatment of dystonia (EPS)
Anticholinergics – injectable if needed
treatment of akathisia
beta blockers, anticholinergics
treatment of parkinsonism
anticholinergics, amantadine
Dopamine does what to ACh
suppresses
Dopamine blockade ___ ACh
increases
EPS caused by
decreased dopamine and increased ACh
improvement of EPS by
anticholinergics
mechanism of tardive dyskinesia
blockade of receptors in nigrostriatal dopamine pathway causes up-regulation, increased ACh
increased risk of TD w/
age > 50
dose
total exposure
mood disorder
anticholinergic side effects (M1)
constipation, blurred vision, dry mouth, drowsiness
antihistaminergic side effects (H1)
weight gain, drowsiness
anti-alpha adrenergic side effects
dizziness, decreased BP, drowsiness
neuroleptic malignant syndrome
life-threatening condition of
hyperpyrexia, autonomic instability, muscle rigidity, and delirium
Death occurs secondary to arrhythmia, rhabdomyolysis or respiratory failure
Discontinue the antipsychotic, aggressive hydration
Mortality rate of 20-30%
how to increase compliance
depot preparations
why was clozapine originally withdrawn
agranulocytosis